提名人上海现代制药股份有限公司（以下简称公司）董事会，现提名邵瑞庆 为公司第九届董事会独立董事候选人，并已充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被提名人已同意 出任公司第九届董事会独立董事候选人（参见该独立董事候选人声明）。提名人 认为，被提名人具备独立董事任职资格，与公司之间不存在任何影响其独立性的 关系，具体声明并承诺如下： 独立董事提名人声明与承诺 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公 ...

独立董事提名人声明与承诺 提名人上海现代制药股份有限公司（以下简称公司）董事会，现提名吴范宏 为公司第九届董事会独立董事候选人，并已充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被提名人已同意 出任公司第九届董事会独立董事候选人（参见该独立董事候选人声明）。提名人 认为，被提名人具备独立董事任职资格，与公司之间不存在任何影响其独立性的 关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公 ...

二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； 独立董事候选人声明与承诺 本人邵瑞庆，已充分了解并同意由提名人上海现代制药股份有限公司（以下 简称公司）董事会提名为公司第九届董事会独立董事候选人。本人公开声明，本 人具备独立董事任职资格，保证不存在任何影响本人担任上海现代制药股份有限 公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明材料。 （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职） 问题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定（如适用）； （二）《中华人民共和国 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-091 上海现代制药股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第三次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 24 日 10 点 00 分 召开地点：上海市浦东新区建陆路 378 号 B1 楼五楼会议室 (五)网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 24 日 至2025 年 12 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东 ...

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has received a drug registration certificate for Hydromorphone Hydrochloride Injection, marking a significant step in expanding its product line in the analgesic sector [1][3]. Group 1: Drug Information - The drug is named Hydromorphone Hydrochloride Injection, with a specification of 1ml:2mg and classified as a Class 3 chemical drug [1]. - The drug registration certificate number is 2025S03532, and the approval number is 国药准字H20256055, with a validity period of 18 months [1]. - The production facility is located in Langfang Economic and Technological Development Zone, and the drug is intended for patients requiring opioid analgesia [2]. Group 2: Market and R&D Situation - Sales figures for Hydromorphone Hydrochloride Injection in public medical institutions over the past three years were RMB 41.34 million in 2022, RMB 74.84 million in 2023, and RMB 71.68 million in 2024 [2]. - The cumulative R&D investment for the Hydromorphone Hydrochloride Injection project is approximately RMB 4.728 million [2]. - Other companies, such as Yichang Renfu Pharmaceutical Co., Ltd., have also obtained registration certificates for the same drug [2]. Group 3: Impact on the Company - The approval of the drug registration certificate allows the company to produce and sell the product in the domestic market, enhancing its competitive position in the analgesic market [3][4]. - This development is expected to positively influence the company's future growth, although it will not have a significant immediate impact on current operating performance [4].

Core Points - The company, China National Pharmaceutical Group Modern, announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has received the drug registration certificate for hydromorphone hydrochloride injection from the National Medical Products Administration [2] Group 1 - The approval of the drug registration certificate indicates a significant regulatory milestone for the company [2] - The hydromorphone hydrochloride injection is expected to enhance the company's product portfolio in the pharmaceutical market [2]

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

Group 1 - The core point of the article is that Guoyao Modern has received approval from the National Medical Products Administration for its product, Hydromorphone Hydrochloride Injection, which is expected to impact its revenue positively [1] - Guoyao Modern's revenue composition for the year 2024 is as follows: 49.84% from formulations, 47.53% from intermediates and active pharmaceutical ingredients, 2.44% from other businesses, and 0.19% from health-related sectors [1] - As of the report, Guoyao Modern has a market capitalization of 13.8 billion yuan [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (国药工业), has received the drug registration certificate for Hydromorphone Hydrochloride Injection from the National Medical Products Administration [1] Group 1 - The drug Hydromorphone, also known as Dihydromorphinone, is a semi-synthetic opioid alkaloid that has been in clinical use since 1926 [1] - Hydromorphone Hydrochloride Injection is indicated for patients requiring opioid analgesia [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industry Co., Ltd. (国药工业), has received approval from the National Medical Products Administration for the drug registration certificate of Hydromorphone Hydrochloride Injection [1] Group 1 - The drug Hydromorphone, also known as dihydromorphinone, is a semi-synthetic opioid alkaloid that has been in clinical use since 1926 [1] - Hydromorphone Hydrochloride Injection is indicated for patients requiring opioid analgesia [1]